JPMorgan lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Overweight rating on the shares. The firm updated estimates following the recent Eylea biosimilar ...

Regeneron (NASDAQ:REGN) shares trended higher pre-market Friday after JPMorgan upgraded the stock to Overweight from Neutral, noting several key catalysts in 2023, including the upcoming launch of ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price raised by JPMorgan Chase & Co. from $1,150.00 to $1,200.00 in a report released on Friday morning, Benzinga reports.

This comprehensive analysis examines Regeneron's current position, future prospects, and the factors that could shape its performance in the coming years. Regeneron Pharmaceuticals has built its ...

This comprehensive analysis examines Regeneron's current position, recent developments, and future prospects to provide investors with a clear picture of the company's potential. Regeneron ...

This comprehensive analysis examines Regeneron's current position, future prospects, and the factors that could shape its performance in the coming years. Regeneron has demonstrated strong ...